Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 5/20 | 0.72 |
| ▸ | ESR1 | P03372 | 5/20 | 0.72 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.70 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.70 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.70 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.57 |
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | TDP2 | O95551 | 2/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8027630 | 0.89 | ESR1 (0.58) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL9007262 | 0.89 | ESR2 (0.91) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL6440249 | 0.89 | ESR2 (0.91) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL13400666 | 0.87 | ESR2 (0.88) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL28160715 | 0.87 | RPS6KB1 (0.57) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL2329244 | 0.85 | ESR1 (0.61) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL6440186 | 0.84 | ESR2 (1.00) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL8021778 | 0.84 | ESR2 (0.88) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL22414155 | 0.84 | RPS6KB1 (0.54) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL16438194 | 0.84 | RPS6KB1 (0.54) | ESR2ESR1GRIA1CACNG8CACNG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517897-A2 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20040002524-A1 | Benzimidazole compounds and their use as estrogen agonists/antagonists | CHESWORTH RICHARD (US) | 2004-01-01 | — | — | US | disclosed |
| WO-2004000817-A2 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002524-A1 | Benzimidazole compounds and their use as estrogen agonists/antagonists | ESR1, GPER1, ESR2 | ESR2 3/4885ESR1 1/4885GRIA1 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.